The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to ...

A one-year prospective study found no correlation between atherosclerosis and extremely high cholesterol levels in 100 ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Ferhaan Ahmad, M.D., Ph.D., FAHA, is the new editor-in-chief of Circulation: Genomic and Precision Medicine, a peer-reviewed scientific journal published by the American Heart Association, effective ...

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Squibb “announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos for the treatment of adult patients with symptomatic New ...

Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that ...